Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 4/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030377 | 1.00 | TSPO (0.60) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3034975 | 0.92 | TSPO (0.66) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL13217925 | 0.92 | TSPO (0.66) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3022501 | 0.92 | TSPO (0.60) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL13217931 | 0.92 | TSPO (0.60) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3035751 | 0.88 | TSPO (0.78) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL13217932 | 0.88 | TSPO (0.78) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL13217935 | 0.87 | TSPO (0.65) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3022530 | 0.87 | TSPO (0.65) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL3016161 | 0.86 | GABRA2 (0.56) | TSPONR1I2ABCB11ALBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209345-A1 | Fluorinated Ligands for Targeting Peripheral Benzodiazepine Receptors | GABRA6, GABRA1, GABRA2 | TSPO 41/4885NR1I2 38/4885ABCB11 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.